LLY compared with SMMT: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

SMMTSummit Therapeutics Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

SMMTSummit Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

SMMT1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−8.81%—

= impliedLLY realized, solidSMMT realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

LLYELI Lilly & Co

1,418.01· pre 1,409.97· delayed

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

SMMTSummit Therapeutics Inc.

14.81· pre 14.81· delayed

Pre-marketNov 3 '26delayed

Mkt cap$11.8BRevenue—Revenue—

Compare

Pre-marketNov 3 '26delayed

LLYELI Lilly & Co

SMMTSummit Therapeutics Inc.

1,418.01pre 1,409.97delayed

Price

14.81pre 14.81delayed

$1.3T

Mkt cap

$11.8B

Q3 FY26$24.4B

Revenue

—

FY25$65.2B

Revenue

—

LLY1,418.01vsSMMT14.81Pre-marketNov 3 '26delayed